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Abstract, ras genes are thought to play an important role in 
human cancer since they have been found to be activated 
frequently in several types of human tumors. From 
preliminary studies it has been found however, that ras 
mutations are extremely rare in breast tumors and therefore it 
was of interest to examine the frequency of such mutations. 
In this study we examined 65 cases of primary breast 
carcinomas from paraffin blocks, for the presence of point 
mutations in codons 12 of the K-ras and Η-ras genes. The 
polymerase chain reaction (PCR) technique was used to 
amplify a codon 12 containing 157 bp and a 312 bp region of 
the K-ras and the Η-ras genes respectively, followed by 
restriction fragment length polymorphism (RFLP) analysis to 
identify the point mutations. Eight out of the 65 tumors 
(12.3%) were found to carry a K-ras mutation in codon 12 
but none was found to carry a Η-ras mutation. It is 
suggested that the mutational activation of the K-ras gene 
may be involved in the development of a small percentage of 
breast tumors. 
Introduction 
It appears that ras gene mutations can be found in a variety 
of tumor types, although the incidence varies greatly. The 
highest incidence is found in adenocarcinomas of the 
pancreas (90%), the colon (50%) and in thyroid tumors 
(50%). For some tumor types a relationship may exist 
between the presence of a ras mutation and clinical or 
histopathological features of the tumor (1). 
Breast cancer is of startlingly high incidence (approaching 
1 in 9 women), but unfortunately current therapies for the 
disease are inadequate once it has metastasized. The disease 
is characterized by excessive morbidity and mortality. 
Normal as well as malignant growth is regulated by 
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endocrine hormones and by local tissue factors, such as 
polypeptide growth factors. Breast carcinomas seem to 
progress as hyperplastic ductal or lobular epithelial growth, 
acquiring progressive genetic changes (including those of 
oncogenes and tumor suppressor genes) leading to clonal 
outgrowths of progressively malignant cells (2). 
The chemical induction of breast adenocarcinomas in 
pubescent rats is a widely used model of carcinogenesis 
because the resulting tumors are histologically and 
behaviorally identical to human breast tumors. Notably 85% 
of these rat mammary carcinomas carry transforming ras 
mutations (3,4). Likewise, many investigators have reported 
that the mutational activation of ras oncogenes is likely 
involved in the etiology or progression of human breast 
cancer, particularly since the ras p21 protein has been shown 
to mediate autocrine production of growth factors in 
transformed cells and even bypass the estrogen depedency of 
human breast cancer cell lines (5,6). To date, however, few 
human breast cancer specimens have been analysed for the 
presence of transforming genes, although several human 
breast cancer cell lines have been shown to contain 
mutationally activated ras oncogenes (7). 
Rochlitz et al (8) have found the emergence of a K-ras 
mutation in codon 12 in the terminal stages of breast cancer 
progression, but other investigators were able to identify such 
mutations only in a primary tumor (9). Using oligonucleotide 
hybridization analysis, Spandidos has detected point 
mutations at amino acid position 12 (glycine to valine) of H-
ras in 2/24 breast carcinomas tested (10). 
Additionally many investigators have reported 
overexpression of the ras-encoded p21 proteins in malignant 
breast carcinomas (11,12), although the role of this 
overexpression in breast carcinogenesis has not been 
determined. 
In this study we examined 65 cases of primary breast 
carcinomas from paraffin blocks, for the presence of point 
mutations in codon 12 of the K-ras and H-ras genes and 
found 8 cases (12.3%) carrying a K-ras mutation. 
Materials and methods 
Tumor specimens. Formalin fixed and paraffin-embedded 
tissue samples from 65 patients, with a diagnosis of primary 
breast carcinoma, were identified in the files of the Pathology 
Department, Medical School, University of Ioannina. 
Hematoxylin-eosin stained sections from all paraffin blocks 
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were reviewed to reconfirm the tumor type and grade and 
representitive blocks (one per case) were selected for further 
analysis. 
DNA extraction. Four or five 10 μπι thick sections from 
paraffin-embedded tissues were placed in 1.5 ml tubes and 
300 μΐ digestion buffer, containing 100 raM NaCl, 10 mM 
Tris-HCl, 25 mM EDTA, 0.5% SDS pH 8.0 and 0.1 mg/ml 
proteinase Κ was added. Samples were then incubated for 1 h 
at 60°C. Fresh proteinase Κ was added at the same 
concentration and the incubation was continued at 37°C 
O/N. The samples were then extracted once with phenol/ 
chloroform and once with chloroform. The upper aqueous 
phase was transferred into fresh tubes and DNA was 
precipitated with the addition of 750 μΐ ethanol and 20 μΐ 5M 
NaCl. DNA was recovered with centrifugation for 15 min at 
4°C, washed twice with cold 70% ethanol and resuspended in 
20 μΐ double distilled water. 
Oligonucleotide primers and PCR amplification. The 
oligonucleotides used for K-ras and Η-ras codons 12 have 
been previously described (13,14). One μΐ of the extracted 
DNA of each sample was amplified in a volume of 50 μΐ 
under the following conditions: 
K-ras amplification: The reaction solution contained 10 
mM Tris-HCl pH 8.3, 50 mM KCl, 3.5 mM MgCl2, 0.01% 
gelatin, 200 μΜ of each dNTP, 100 pmoles of each primer 
and 2.5 U Taq polymerase (Gibco). Samples were subjected 
to 40 cycles of amplification under the following conditions: 
94°C for 50 sec; 59°C for 45 sec and 72°C for 50 sec. 
Η-ras amplification: The reaction solution contained 16.6 
mM (NH4)2S04, 10 mM, ß-mercaptoethanol, 6.7 mM MgCl2, 
67 mM Tris-HCl pH 8.8, 1.7 mg BSA, 6.7 μΜ EDTA, 200 
μΜ of each dNTP, 75 pmoles of each primer and 2.5 U Taq 
polymerase (Gibco). Samples were subjected to 35 cycles of 
amplification under the following conditions: 94°C for 50 
sec; 60°C for 40 sec and 72°C for 50 sec. 
RFLP analysis. K-ras: 10-20 μΐ aliquots of the amplification 
products were digested for 3 h with 40 U BstNI. 
H-ras: 10-20 μΐ aliquots of the amplification products 
were digested O/N with 40 U Mspl. 
Enzymes were supplied by New England Biolabs and the 
conditions followed for digestion were those recommended 
by the supplier. Incubation temperatures were 60°C for BstNI 
and 37°C for Mspl. Digestion products were electrophoresed 
through an 8% native Polyacrylamide gel. Gels were stained 
with ethidium bromide and photographed on a UV light 
transilluminator. As positive control the cell lines SW480 for 
K-ras and EJ for Η-ras gene were used. 
Results 
After reviewing the selected tissue sections, the histological 
classification (15) and grading (16,17) was as follows: There 
were 52 infiltrating ductal carcinomas Grade I-III (NOS type 
- 40 cases, Comedo type - 3 cases, Papillary type - 1 case, 
Mucinous type - 2 cases, Medullary type - 3 cases, Tubular 
type - 1 case and Cribriform type - 2 cases), 11 infiltrating 
lobular carcinomas Grade I-III and 2 ductal carcinomas 
in situ. 
Figure 1. K-ras amplification products digested with BstNI and 
electrophoresed through an 8% Polyacrylamide gel. SW480 cell line: 
positive control, tumors no 1,2,4: normal, tumors no 3,5: mutant. 
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Figure 2. Η-ras amplification products digested with Mspl and 
electrophoresed through an 8% Polyacrylamide gel. Tumors no 1-6: normal, 
EJ cell line: positive control. 
In this study we examined the presence of mutations in 
codon 12 of the K-ras and Η-ras genes in these 65 cases of 
primary breast carcinomas. Using the known cell lines 
SW480 and EJ, with mutations in codon 12 of the K-ras and 
Η-ras gene, respectively, experiments were performed to 
establish the PCR and RFLP techniques. Eight out of the 65 
tumors (12.3%) were found to carry a point mutation in 
codon 12 of K-ras (for representative examples see Fig. 1), 
while there was no evidence for point mutations in codon 12 
of Η-ras (for representative examples see Fig. 2). Our study 
was limited to codon 12 of the K-ras gene, since mutations 
preferentially occur in this codon (18). The K-ras mutations 
were found in 1 out of 23 patients with infiltrating ductal 
NOS type Grade II, 4 out of 16 with infiltrating ductal NOS 
type Grade III, 2 out of 6 with infiltrating lobular type Grade 
II and 1 out of 4 with infiltrating lobular type Grade III. No 
K-ras or Η-ras mutation was found in Grade I primary breast 
carcinomas. The results of PCR analysis of the 65 samples 
for K-ras mutations are summarized in Table I. 
These data do not indicate a correlation between the 
presence of point mutations and the histological type of the 
tumor. However, it is notable that mutations were found only 
in tumors with Grade II and III, with a higher incidence in 
Grade III. 
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Table I. K-ras gene mutations in codon 12 in breast tumors. 
Histological 
type of tumor 
Grade Total 
No. of patients 
1 
23 
16 
3 
1 
1 
1 
3 
1 
1 
1 
1 
6 
4 
2 
No. of patients 
with K-ras mutation 
none 
1 
4 
none 
none 
none 
none 
none 
none 
none 
none 
none 
2 
1 
none 
Infiltrating ductal 
Non otherwise specified type 
Non otherwise specified type 
Non otherwise specified type 
Comedo type 
Papillary type 
Mucinous type 
Mucinous type 
Medullary type 
Tubular type 
Cribriform type 
Cribriform type 
Infiltrating lobular 
Infiltrating lobular 
Infiltrating lobular 
Ductal carcinomas in situ 
I 
II 
III 
II 
I 
I 
II 
III 
1 
I 
II 
I 
II 
III 
Total number 65 8(12.3%) 
Discussion 
At the molecular level, breast cancer may be the result of a 
complex, dynamic, and stochastic process where there is 
more than one way to accomplish each of the steps necessary 
for malignant growth. The well documented biological 
heterogeneity of breast tumors may arise from the many 
possible molecular changes that can accomplish a given step 
with variable efficiency. Alternatively, this heterogeneity 
may also reflect various possible orders of acquiring the sum 
of steps necessary for malignant growth. As a result it seems 
likely that multiple genetic alterations act in concert to 
produce an invasive breast carcinoma with the ability to 
metastasize to distant organ sites. It is also suggested that the 
loss of specific chromosomal regions collaborates during 
progression of primary breast cancer (19), even by triggering 
activation of an oncogene by gene amplification due to the 
instability in the nucleus of malignant cells. Amplification of 
the erbB-2 oncogene in addition to loss of heterozygosity on 
chromosome 17 might promote breast cancer by affecting the 
proliferation of tumor cells (20). 
Previous observations (8,9) are substantiated by the 
present study showing that involvement of K-ras gene 
mutations can occur in breast carcinoma, albeit at a low 
frequency. Considering the low frequency of activated K-ras, 
little can be concluded about the malignant potential of a 
tumor containing an activated ras gene. However, this low 
frequency of ras mutations provides evidence for an 
etiological difference between spontaneous human breast 
tumors and carcinogen-induced animal models of breast 
cancer which bear a high incidence of ras mutations (3,4). 
This molecular analysis also illustrates the biological and 
probable etiological differences that exist between breast 
adenocarcinomas and others histologically similar 
adenocarcinomas which have a high incidence of ras 
mutations (1). In addition the presence of point mutations 
(with an incidence of 12.3%) only in primary carcinomas 
with higher Grade (II and III) indicates that the mutational 
activation of the K-ras oncogene may be a late event and 
could play a role in the metastatic progression of human 
breast cancer. The study described here contributes to our 
understanding of tumor development and progression in 
breast cancer and to the future application of DNA diagnosis 
for clinical purposes; e.g., to estimate the prognosis of 
patients. It is suggested that the mutational activation of K-
ras may alter the tumorigenic behaviour of a cell that already 
has malignant potential, thus being involved in the process of 
breast carcinogenesis. 
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